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Purpose: The aim of this study was to investigate the
efﬁcacy and tolerability of GCSB-5, a mixture of 6 puriﬁed
herbal extracts, in treating hand osteoarthritis (OA).
Methods: A randomized, double-blind, placebo-
controlled trial enrolled 220 patients with hand OA
who had baseline a visual analog scale joint pain score
of 430 of 100 mm at 3 hospitals between September
2013 and November 2014. After randomization,
patients were allocated to receive oral GCSB-5 600
mg or placebo, bid for 12 weeks. The primary end
point was the change in the Australian/Canadian OA
Hand Index (AUSCAN)-deﬁned pain score at 4 weeks
relative to baseline. Secondary end points included the
frequency Outcome Measures in Rheumatology–OA
Research Society International (OMERACT-OARSI)-
deﬁned response at 4, 8, 12, and 16 weeks after
randomization.
Findings: The allocated treatment was received by
109 and 106 patients in the GCSB-5 and placebo
groups, respectively. At 4 weeks, the median (inter-
quartile range) change in AUSCAN pain score relative
to baseline was signiﬁcantly greater in the GCSB-5
group than in the placebo group (–9.0 [–23.8 to –0.4]
vs –2.2 [–16.7 to 6.0]; P ¼ 0.014), with sustained
improvement at 8, 12, and 16 weeks (P ¼ 0.039). The
GCSB-5 group also had a signiﬁcantly greater OMER-
ACT-OARSI–deﬁned response rate than did the pla-
cebo group at 4 weeks (44.0% vs 30.2%), 8 weeks
(51.4% vs 35.9%), 12 weeks (56.9% vs 40.6%), and
16 weeks (50.5% vs 37.7%) (P ¼ 0.0074). The 2
treatments exhibited comparable safety proﬁles.1858Implications: GCSB-5 was associated with im-
proved symptoms of hand OA, with good tolerability,
in these patients. GCSB-5 may be a well-tolerated
alternative of, or addition to, the treatment of hand
OA. ClinicalTrials.gov identiﬁer: NCT01910116.
(Clin Ther. 2016;38:1858–1868) & 2016 The Au-
thors. Published by Elsevier HS Journals, Inc.
Key words: GCSB-5, hand, osteoarthritis, random-
ized clinical trial.INTRODUCTION
Osteoarthritis (OA) of the hand preferentially involves
the proximal and distal interphalangeal joints and the
ﬁrst carpometacarpal joints in the middle-aged and
elderly populations. Symptomatic hand OA is more
prominent in women than in men.1 It is often
associated with considerable disability and a reduced
quality of life that are comparable to the effects of
rheumatoid arthritis.2–4 The mainstay treatment of
hand OA is to control the symptoms with a combi-
nation of nonpharmacologic and pharmacologic in-
terventions.5,6 An oral NSAID, acetaminophen, or an
opioid-based analgesic is often recommended. How-
ever, ﬁndings from only a few well-designedVolume 38 Number 8
J.K. Park et al.randomized, controlled trials (RCTs) have supported
the efﬁcacy of these drugs in hand OA.7 In addition,
the increase in the prevalence of hand OA with age is
problematic because long-term treatment with
NSAIDs often is associated with serious gastrointesti-
nal side effects, especially in elderly patients.8–10
Moreover, in clinical practice, even the optimal
combination of pharmacologic and nonpharmaco-
logic managements fails to deliver comprehensive
symptom control in a signiﬁcant subset of patients.7,11
Thus, there is an unmet need for new therapeutic
options for hand OA.
GCSB-5 is a mixture of 6 puriﬁed herbal extracts at
a ﬁxed ratio.12 These herbs have been used in
traditional Chinese medicine for treating diverse
inﬂammatory conditions. Their anti-inﬂammatory,
analgesic, and chondroprotective effects have been
observed in both animals and humans.13,14 These
properties suggest that GCSB-5 may be a useful
addition to the management of hand OA.
This study was conducted to investigate the efﬁcacy
and tolerability of GCSB-5 for treating hand OA.PATIENTS AND METHODS
Study Population
Patients with hand OA who were aged 440 years
and had a visual analog scale (VAS) joint pain score
exceeding 30 of 100 mm in the preceding 48 hours were
included. Hand OA was diagnosed on the basis of the
1990 American College of Rheumatology–deﬁned cri-
teria for hand OA.15 These classiﬁcation criteria include
hand pain, aching, and/or stiffness in the presence of
bony enlargement or deformity in selected hand joints.
The use of these criteria helped to recruit a relatively
homogenous subset of patients with hand OA.
Patients who were taking an NSAID, analgesic agent,
glucosamine, or other OA medication underwent wash-
out for 2 weeks before receiving the allocated treatment.
During the washout period, acetaminophen was al-
lowed as a rescue medication until 24 hours before the
screening visit. Patients were excluded if they had a
history of any of the following: hand joint surgery;
intra-articular injection of a hand joint with a cortico-
steroid or hyaluronic acid within the preceding 3
months; GCSB-5 use; stroke, myocardial infarction, or
coronary angioplasty; gastrointestinal bleeding; and/or
chronic kidney disease. Women who were pregnant or
breast-feeding were also excluded.August 2016Study Design
This prospective, multicenter (3 active sites), random-
ized, double-blind, placebo-controlled study (Clinical-
Trials.gov identiﬁer: NCT01910116) investigated the
efﬁcacy and tolerability of GCSB-5 600 mg BID in
treating hand OA. The study was conducted at 3 tertiary
medical centers between September 2013 and November
2014. The study protocol was approved by the institu-
tional review boards at the participating centers. Written
informed consent was received from all participating
patients. The study was conducted in accordance with
the recently revised Declaration of Helsinki.16
Randomization and Blinding
The Medical Research Collaboration Center of a
participating medical center generated a randomiza-
tion table that was stratiﬁed by center. The allocation
ratio in this parallel-arm study was 1:1. The allocation
table was given to independent pharmacists at each
participating center and was concealed from the
researchers who enrolled and assessed the study partic-
ipants until the end of the study. The study design was
not changed after commencement. The study medica-
tion and placebo were identical in appearance, odor,
and taste, and were provided by Green Cross Corpo-
ration (Yongin, Republic of Korea).
Intervention
GCSB-5 is a powdered extract of 6 herbs at a ﬁxed
ratio (Saposhnikovia divaricata Schischkin, Achyr-
anthes bidentata Blume, Acanthopanax senticosus
Harms, Cibotium barometz J. Smith, Glycine max
Merrill, and Eucommia ulmoides Oliver). The ingre-
dients of the product were validated by HPLC anal-
ysis. GCSB-5 was further standardized for quality
control according to the regulations imposed by the
Korea Food and Drug Administration.13 In Korea,
GCSB-5 is indicated for the treatment of OA.
After randomization, patients received oral GCSB-5
600 mg or placebo, BID for 12 weeks. Independent
pharmacists dispensed the study drugs according to
the randomization table. For the evaluation of the
residual effects of GCSB-5, patients in both groups
were observed for an additional 4 weeks after the 12-
week intervention period.
Prohibited Treatments
The use of medications that may have inﬂuenced
the symptoms of OA was prohibited. These1859
Clinical Therapeuticsmedications included NSAIDs, analgesic agents, glu-
cosamine sulfate, glucosamine hydrochloride, and
chondroitin sulfate. Intra-articular injection was also
prohibited. Acetaminophen 650 mg TID for up to 7
days was allowed as a rescue therapy.
Efficacy and Tolerability Assessments
All patients underwent comprehensive clinical and
laboratory testing (including complete blood count,
liver function testing, serum blood urea nitrogen,
creatinine, and urinalysis) at baseline and at 4, 8, 12,
and 16 weeks after randomization. The Korean
version of the Australian/Canadian OA Hand Index
(AUSCAN), which has been validated,17 was the main
tool used for measuring outcomes in this study.
AUSCAN-deﬁned pain and function scores were nor-
malized according to a 0- to 100-point scale.18 The
AUSCAN index is a tri-dimensional, self-administered
questionnaire that assesses pain, disability (dysfunction),
and joint stiffness in hand OA. The questionnaire
contains 15 items (5 on pain, 1 on stiffness, and 9 on
disability) that were scored on a 100-mm VAS by each
participant. AUSCAN pain and function scores were
normalized according to a 0- to 100-point scale.
The primary efﬁcacy end point was the change in
AUSCAN pain score at 4 weeks relative to baseline.
Secondary end points included the changes from the
baseline in the following variables: AUSCAN pain
score at 8, 12, and 16 weeks; AUSCAN stiffness score;
AUSCAN function score; patient global assessment;
physician global assessment; and Outcome Measures
in Rheumatology–OA Research Society International
(OMERACT-OARSI) response criterion D, at 4, 8,
12, and 16 weeks. General health was assessed by
each patient using a patient global assessment tool,
and by investigators using a physician global assessment
tool. Both tools used the100-mm VAS, in which 0 mm
represented the best health state, and 100 mm, the
worst health state. The OMERACT-OARSI set of
response criteria was used for determining clinically
meaningful improvement on 3 symptom domains: pain,
function, and patient global assessment. A patient was
deemed to be an OMERACT-OARSI–deﬁned res-
ponder if s/he showed an improvement of Z50%
relative to baseline on the pain or function domain,
with an absolute change ofZ20, or an improvement of
Z20% relative to baseline in at least 2 of the 3 domains
(pain, function, and patient global assessment), with
an absolute change of Z10.19 The use of rescue1860medication was captured at each visit. The end points
were not changed after study commencement.
All types of adverse events (AEs) were captured at
each visit.
Statistical Analysis
Sample Size Calculation
We reported previously that after 4 weeks of
placebo administration, the mean (SD) improvement
in AUSCAN pain score in patients with hand OA was
þ7.8 (23.6) (on a 0–100 scale).20 Assuming that
GCSB-5 improves the AUSCAN pain score by 410
relative to placebo, and assuming an α level of 0.05 (2-
tailed), a power of 0.80, and a dropout rate of 20%,
the sample size calculation revealed that 220 patients
were needed for enrollment.21–24
Outcomes Analyses
A modiﬁed intent-to-treat analysis was performed
using data from all randomized patients who received
Z1 dose of the allocated intervention. The last-
observation-carried-forward method was used for
imputing missing data. The 2 groups were compared
in terms of demographic and clinical variables using
an independent t test, χ2 test, or Fisher exact test, as
appropriate. The efﬁcacy end points at 4, 8, 12, and
16 weeks did not follow a normal distribution (P 4
0.05 by both the Kolmogorov-Smirnov and Shapiro-
Wilk tests). Therefore, differences between the 2
groups in terms of the primary end points were
evaluated using the Wilcoxon rank-sum test. The
primary and secondary efﬁcacy end points measured at
4, 8 12, and 16 weeks were examined by nonparametric
repeated measures of ANOVA for continuous variables
and a generalized estimating equation for categorical
variables.25 The interactions between groups and time
were examined. Sensitivity analyses were conducted on
the primary end points using the complete dataset, and
multiple imputation of the dataset by fully conditional
speciﬁcation. P o 0.05 was considered to indicate
statistical signiﬁcance. All analyses were performed
using SAS version 9.2 (SAS Institute, Cary, NC).RESULTS
Patients’ Demographic and Clinical
Characteristics
In total, 230 patients with hand OA were screened.
Of these, 220 (147, 43, and 30 patients from each ofVolume 38 Number 8
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Figure 1. Flow diagram of patient disposition in this study in patients with hand osteoarthritis treated with
GCSB-5 600 mg or placebo BID for 12 weeks. LFT ¼ liver function test.
J.K. Park et al.the 3 centers) were randomly assigned to the GCSB-5
arm (n ¼ 110) or the placebo arm (n ¼ 110). After
randomization, 109 patients in the GCSB-5 arm and
106 in the placebo arm received the allocated treat-
ment. The data from those patients were included in
the analysis (Figure 1).
The GCSB-5 and placebo groups did not differ
signiﬁcantly in terms of baseline characteristics.
They were, on average, 60.7 (7.2) and 59.4 (8.0)
years of age, respectively, and females predominated
in both groups (91.7% and 92.5%, respectively).August 2016The 2 groups did not differ signiﬁcantly in terms of
weight, height, body mass index, duration of hand
OA, OA disease activity, or prior treatments
(Table I).
Efficacy
The improvements in the AUSCAN pain score were
signiﬁcantly greater in the GCSB-5 group than in the
placebo group over the 16-week study period (P ¼
0.0052). At 4 weeks, the median (interquartile range)
improvement in the AUSCAN pain score relative to1861
Table I. Baseline characteristics of the study patients with hand osteoarthritis (OA) treated with GCSB-5 600
mg or placebo BID for 12 weeks (modified intent-to-treat population).
Characteristic GCSB-5 (n ¼ 109) Placebo (n ¼ 106) P
Age, mean (SD), y 60.7 (7.2) 59.4 (8.0) 0.211
Female, no. (%) 100 (91.7) 98 (92.5) 0.847
Weight, mean (SD), kg 58.9 (7.4) 59.0 (8.1) 0.917
Height, mean (SD), cm 156.7 (6.7) 157.0 (6.0) 0.774
Body mass index, mean (SD), kg/m2 23.9 (2.5) 23.9 (2.8) 0.927
Duration of hand OA, mean (SD), mo 28.6 (46.8) 31.7 (47.2) 0.631
Family history of OA, no. (%) 30 (27.5) 25 (23.6) 0.508
Baseline scores, mean (SD) (ranges, 1–100)
AUSCAN pain score 49.7 (16.7) 48.2 (19.9) 0.529
AUSCAN stiffness score 55.2 (23.8) 60.4 (22.8) 0.103
AUSCAN function score 47.2 (21.8) 46.2 (23.9) 0.751
Patient global assessment 49.6 (16.5) 50.1 (16.3) 0.824
Physician global assessment 43.1 (11.1) 41.5 (13.0) 0.324
ESR, mean (SD), mm/h (normal, o20 mm/h) 14.2 (14.6) 13.3 (10.0) 0.593
hs-CRP,† mean (SD), mg/dL (normal, o0.5 mg/dL) 0.09 (0.11) 0.12 (0.26) 0.164
Prior treatment, no. (%)
NSAIDs 36 (33.0) 36 (34.0) 0.885
Glucosamine 14 (12.8) 13 (12.3) 0.898
Acetaminophen 9 (8.3) 10 (9.4) 0.761
Tramadol 8 (7.3) 11 (10.4) 0.433
Diacerein 5 (4.6) 3 (2.8) 0.722*
Others 1 (0.9) 3 (2.8) 0.365*
AUSCAN ¼ Australian/Canadian Osteoarthritis Hand Index; CRP ¼ C-reactive protein; ESR ¼ erythrocyte sedimentation
rate; OA ¼ osteoarthritis.
*Fisher exact test. Remaining P values were generated by using an independent t test for continuous variables or χ2 test for
categorical variables.
†CRP values were not available in 1 patient in the GCSB-5 group and in 1 patient in the control group.
Clinical Therapeuticsbaseline was greater in the GCSB-5 group than in the
placebo group (–9.0 [–23.6 to –0.4] vs –2.2 [–16.6 to
6.0], respectively; P ¼ 0.014) (Figure 2A). The
improvement remained greater in the GCSB-5 group
at 8 weeks (–13.4 [–26.2 to 0] vs –2.2 [–17.4 to 4.8])
and at 12 weeks (–14.6 [–30.4 to 0] vs –8.0 [–25.0 to
7.8]) (Table II). At 4 weeks after treatment
discontinuation (week 16), the GCSB-5 group con-
tinued to exhibit improved AUSCAN pain scores
relative to baseline, whereas the AUSCAN pain scores
in the placebo group deteriorated after treatment
discontinuation. Thus, at the 16-week time point,
the GCSB-5 and placebo groups differed in terms of
AUSCAN pain score improvement (–15.6 [–28.2 to 0]1862vs –4.4 [–24.8 to 7.2]). The improvements in the
AUSCAN function scores relative to baseline were
signiﬁcantly greater in the GCSB-5 group than in
the placebo group at 4 weeks (–6.8 [–18.9 to 3.6] vs
–3.7 [–13.7 to 6.8]), 8 weeks (–9.8 [–26.9 to 2.6]
vs –4.8 [–18.6 to 7.7]), 12 weeks (–11.0 [–27.8 to 0.8]
vs –2.9 [–18.3 to 6.8]), and 16 weeks (–9.9 [–28.7 to
0.6] vs –4.8 [–18.7 to 9.1]) (P ¼ 0.039). The 2 groups
did not differ in terms of AUSCAN stiffness scores
(Table II). Compared with patients who received
placebo, more patients in the GCSB-5 group fulﬁlled
the OMERACT-OARSI response criteria over the
16-week study period (proportions of fulﬁllment: 4
weeks, 44.0% vs 30.2%; 8 weeks, 51.4% vs 35.9%;Volume 38 Number 8
Week 4 Week 8 Week 12 Week 16
0
20
40
60
50.5
37.7
56.9
40.6
51.4
35.9
44.0
30.2
Placebo
GCSB-5
P=0.0074
OMERACT-OARSI response
R
es
po
nd
er
s 
(%
)
AUSCAN Pain
_30
_20
_10
0
10
Placebo GCSB-5
P=0.014
C
ha
ng
e 
fr
om
 b
as
el
in
e
A B
Figure 2. Outcomes in this study in patients with hand osteoarthritis treated with GCSB-5 600 mg or placebo
BID for 12 weeks. (A) Change in Australian/Canadian Osteoarthritis Hand Index (AUSCAN) pain
score at 4 weeks after randomization. P value for the primary outcome generated by the Mann-
Whitney test. (B) Frequencies of Outcomes Measures in Rheumatology-Osteoarthritis Research
Society International (OMERACT-OARSI)-defined response at various time points. P was generated
using a generalized estimating equation.
J.K. Park et al.12 weeks, 56.9% vs 40.6%; and 16 weeks, 50.5% vs
37.7% [P ¼ 0.0074]) (Figure 2B).
The improvements in patient global assessment
scores relative to baseline were signiﬁcantly greater
in the GCSB-5 group than in the placebo group,
whereas the 2 groups did not differ in terms of
physician global assessment scores. The 2 groups did
not exhibit marked improvements relative to baseline
in terms of the use of rescue medication (Table II)
(Supplementary Table III).
Sensitivity Analysis
At 4 weeks, data were missing in 3 of 109 patients
(2.8%) in the GCSB-5 group and in 4 of 106 patients
(3.8%) in the placebo group. After multiple imputa-
tion of missing values using the fully conditional
speciﬁcation algorithm, the change in AUSCAN pain
score at 4 weeks was signiﬁcantly greater in the
GCSB-5 group than in the placebo group (P ¼
0.024). The difference in the primary end point
remained signiﬁcant when the analysis was performed
using the complete dataset (P ¼ 0.018) (Table III).
Tolerability
The 2 groups had similar rates of AEs (Table IV).
Severe AEs that led to early study withdrawal wereAugust 2016not reported in the GCSB-5 arm. In the placebo
group, two patients discontinued the study medication
due to skin rash (n ¼ 1) and liver function test
abnormality (n ¼ 1). The GCSB-5 group was more
likely to develop upper respiratory infection (14.7%
vs 4.7%; P ¼ 0.02). The 2 groups had similar rates of
gastrointestinal AEs.DISCUSSION
The ﬁndings from this prospective, double-blind,
randomized, placebo-controlled trial suggest that
GCSB-5 treatment was clinically effective for hand
OA and that it had a tolerable safety proﬁle. AUS-
CAN pain scores were improved with GCSB-5 relative
to placebo during the treatment period and at 4 weeks
after discontinuation. Furthermore, the GCSB-5 group
had a signiﬁcantly greater rate of OMERACT-OARSI
response than did the placebo group during the entire
intervention period. This ﬁnding is important because
the OMERACT-OARSI response has been proposed
to be the preferred outcome measure in OA studies.19
Hand OA is one of the most common OA types: its
prevalence ranges between 29% and 76%, and it has
been associated with a serious disease burden.2
However, the current guidelines were based mainly
on the opinions of experts rather than on data from1863
Table II. Changes from baseline in efficacy outcomes in patients with hand osteoarthritis treated with GCSB-5
600 mg or placebo BID for 12 weeks. Data are given as median (interquartile range) unless
otherwise noted.
Outcome GCSB-5 (n ¼ 109) Placebo (n ¼ 106) P
AUSCAN pain 0.0052*
Week 4 –9.0 (–23.6 to –0.4) –2.2 (–16.6 to 6.0)
Week 8 –13.4 (–26.2 to 0.0) –2.2 (–17.4 to 4.8)
Week 12 –14.6 (–30.4 to 0.0) –8.0 (–25.0 to 7.8)
Week 16 –15.6 (–28.2 to 0.0) –4.4 (–24.8 to 7.2)
AUSCAN stiffness 0.2648*
Week 4 –9.0 (–22.0 to 3.0) –6.0 (–23.0 to 6.0)
Week 8 –12.0 (–28.0 to 2.0) –6.0 (–27.0 to 4.0)
Week 12 –14.0 (–36.0 to 0.0) –11.0 (–29.0 to 5.0)
Week 16 –10.0 (–27.0 to 2.0) –8.0 (–27.0 to 5.0)
AUSCAN function 0.0390*
Week 4 –6.8 (–18.9 to 3.6) –3.7 (–13.7 to 6.8)
Week 8 –9.8 (–26.9 to 2.6) –4.8 (–18.6 to 7.7)
Week 12 –11.0 (–27.8 to 0.8) –2.9 (–18.3 to 6.8)
Week 16 –9.9 (–28.7 to 0.6) –4.8 (–18.7 to 9.1)
Patient global assessment 0.0167*
Week 4 –9.0 (–24.0 to 2.0) –3.0 (–15.0 to 6.0)
Week 8 –10.0 (–24.0 to 0.0) –6.0 (–18.0 to 12.0)
Week 12 –11.0 (–30.0 to 1.0) –6.0 (–24.0 to 6.0)
Week 16 –10.0 (–29.0 to 3.0) –8.5 (–21.0 to 9.0)
Physician global assessment 0.0760*
Week 4 –12.0 (–21.0 to 0.0) –7.0 (–19.0 to 1.0)
Week 8 –16.0 (–26.0 to –4.0) –11.5 (–25.0 to 0.0)
Week 12 –19.0 (–29.0 to –5.0) –13.0 (–27.0 to 0.0)
Week 16 –12.0 (–23.0 to 0.0) –6.5 (–20.0 to 1.0)
Acetaminophen rescue, no. (%) 0.4216†
Week 4 7 (6.42) 4 (3.77)
Week 8 10 (9.17) 7 (6.60)
Week 12 4 (3.67) 4 (3.77)
Week 16 4 (3.67) 2 (1.89)
AUSCAN ¼ Australian/Canadian Osteoarthritis Hand Index.
*Nonparametric repeated measure ANOVA.
†Generalized estimating equations were used for generate P values that represent the signiﬁcance of group difference over
16 weeks.
Clinical Therapeuticswell-designed clinical trials.5–7 For example, the efﬁ-
cacy of acetaminophen, which is often suggested as
the initial pharmacologic choice, in hand OA has not
yet been proved by ﬁndings from an RCT. Among
NSAIDs, only ibuprofen and lumiracoxib have been1864studied in RCTs in terms of their efﬁcacy in hand OA
to date.26,27 However, ibuprofen can cause serious
gastrointestinal complications in the elderly popula-
tion,28,29 and lumiracoxib, a selective cyclooxygenase-2
inhibitor with a lower risk for gastrointestinal AEs,Volume 38 Number 8
Table III. Sensitivity analysis of changes from baseline in Australian/Canadian Osteoarthritis Hand Index pain
scores at 4 weeks in patients with hand osteoarthritis treated with GCSB-5 600 mg or placebo BID
for 12 weeks. Data are given as median (interquartile range).
Statistical Set GCSB-5, n Placebo, n P
LOCF* –9.0 (–23.8 to –0.2), 109 –2.2 (–16.7 to 6.0), 106 0.014
FCS† –9.8 (–24.0 to –0.8), 109 –3.8 (–17.2 to 6.0), 106 0.024
Complete dataset –9.8 (–24.0 to –0.8), 106 –3.7 (–17.0 to 6.0), 102 0.018
*Missing data were imputed using last observation carried forward (LOCF).
†Missing data handled with multiple imputation using fully conditional speciﬁcation (FCS). P values were generated by using
Wilcoxon rank sum test.
J.K. Park et al.has been withdrawn from the market due to its
potential for severe hepatotoxicity.30 Moreover,
although NSAIDs are effective in hand OA, their
association with considerable gastrointestinal and
cardiovascular toxicity limits their long-term use.31
Opioid analgesics, which are also frequently
associated with gastrointestinal discomfort, have not
yet been studied in an RCT. The data on
corticosteroid use in hand OA are conﬂicting: 1
small observational study in 36 patients reported
that 120 mg of methylprednisolone IM effectivelyTable IV. Adverse events (AEs) in patients with and ha
placebo BID for 12 weeks. Data are given as
Parameter G
Any AE
AEs leading to treatment discontinuation
Serious AEs
Surgery
Fracture
Liver function abnormality
Skin rash
AEs occurring in 45% of patients
Abdominal discomfort
Upper respiratory infection
Skin rash
Leukopenia
Liver function abnormality
Nausea
August 2016ameliorated OA symptoms, and an RCT in 83
patients reported that with the drug Crx-102 (a
combination of dipyridamole and low-dose predniso-
lone), hand pain was signiﬁcantly reduced, whereas an
RCT in 70 patients reported that 5 mg of oral
prednisolone had no effect on hand pain.24,32,33
However, various complications associated with glu-
cocorticoid limit its long-term use.34 In short, the oral
pharmacologic agents currently recommended for
hand OA require a more solid scientiﬁc background
regarding efﬁcacy and tolerability. Only topicalnd osteoarthritis treated with GCSB-5 600 mg or
no. (%).
CSB-5 (n ¼ 109) Placebo (n ¼ 106)
55 (50.5) 45 (42.5)
0 2 (1.9)
1 (0.9) 4 (3.8)
1 (0.9) 1 (0.9)
0 1 (0.9)
0 1 (0.9)
0 1 (0.9)
17 (15.6) 11 (10.4)
16 (14.7) 5 (4.7)
8 (7.3) 10 (9.4)
9 (8.3) 7 (6.6)
7 (6.4) 7 (6.6)
6 (5.5) 6 (5.7)
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Clinical Therapeuticsdiclofenac gel has been reported to be effective for
hand OA in a well-designed trial.35
That GCSB-5 was associated with a greater
OMERACT-OARSI response rate than was placebo
throughout the intervention period suggests that GCSB-
5 has meaningful clinical efﬁcacy. This ﬁnding is con-
sistent with those from a prior study that reported that
GCSB-5 was noninferior to celecoxib in treating knee
OA.12 Another ﬁnding from the present study was that
the clinical response to GCSB-5 continued after the
treatment was stopped: in the GCSB-5 group, the
improvement in AUSCAN pain score was unabated 4
weeks after treatment discontinuation, whereas the AUS-
CAN pain score in the placebo group had started to
increase at the same time point (Table II). Whether
GCSB-5 may be a disease-modifying OA drug—as
GCSB-5 has been reported in an animal OA model to
protect cartilage structures13—needs further investigation.
Longer-term studies are needed to further investigate the
potential of GCSB-5 as a disease-modifying OA drug—in
particular, studies that assess the optimal GCSB-5 treat-
ment duration and the effect of this agent on structural
changes in hand OA. The low placebo response in the
current study was surprising. A possible explanation is
that placebo responses vary from study to study, as the
clinical characteristics of the enrolled patients might differ
between studies. A similarly low placebo response in a
study in hand OA was reported previously.24
Although the exact mechanism of action of GCGB-
5 is still under investigation, the extracts contained in
GCSB-5 have been reported to have several biological
effects. They exhibit antioxidative effects and reduce
oxidative stress. The anti-inﬂammatory effects are
elicited through the suppression of cyclooxygenase 2
expression; down-regulation of inﬂammatory media-
tors, including interleukin 1β and tumor necrosis
factor α; and inhibition of nitrite oxide. In addition,
GCSB-5 might improve OA-induced cartilage damage
by inhibiting matrix metalloproteinase activity (see
Supplemental Table I in the online version at http://
dx.doi.org/10.1016/j.clinthera.2016.06.016).
Because GCSB-5 and celecoxib have exhibited
comparable efﬁcacy in the treatment of knee OA,
and because the analgesic effect of NSAIDs is usually
clinically apparent within 1 to 2 weeks, we chose the
change in pain at 4 weeks relative to baseline as the
primary end point. Furthermore, changes in pain and
other clinical outcomes measures up to 16 weeks were
included as secondary end points for evaluating1866treatment sustainability. However, as long-term ef-
fects (ie, efﬁcacy and AEs) are crucial for the manage-
ment of chronic disease, a prospective, long-term
study (beyond a 52-week period) is needed for
evaluating the exact role of GCSB-5 in the manage-
ment of hand OA.
Hand OA is a chronic disease that exhibits great
variation. The disease inevitably progresses in half of
patients, leading to high levels of functional limita-
tion.36 These patients might require lifelong treatment,
making the long-term tolerability of oral pharmaco-
logic treatments a major issue. GCSB-5 was compa-
rable to placebo in terms of overall safety proﬁle. In
particular, the GCSB-5 and placebo groups exhibited
similar frequencies of abdominal discomfort (16.5%
and 12.3%, respectively). Interestingly, the GCSB-5
group experienced upper respiratory tract infection
more frequently than did the placebo group (14.7% vs
4.7%) (Table IV). However, an association between
leukopenia and the increased rate of upper respiratory
tract infection was not found (see Supplemental Table II
in the online version at http://dx.doi.org/10.1016/
j.clinthera.2016.06.016). A larger-scale study is needed
for conﬁrming whether GCSB-5 use is associated with
increased risks for upper respiratory tract infection and
leukopenia. The clinical efﬁcacy and tolerability of
GCSB-5 suggest that it may be a well-tolerated alter-
native in patients with hand OA who cannot tolerate
other oral pharmacologic treatments.Study Limitations
A major limitation of the present RCT was that the
study population was composed of ethnic Koreans
only. Whether the present ﬁndings can be generalized
to other ethnic groups requires further investigation.
In addition, a study with longer follow-up is needed to
investigate long-term efﬁcacy and tolerability issues.CONCLUSION
The use of GCSB-5 was associated with meaningful
clinical improvement and was well-tolerated in these
patients with hand OA.ACKNOWLEDGMENTS
This study was funded by the Green Cross Corpo-
ration. This was an investigator-initiated trial; the
company was not involved in the study design,Volume 38 Number 8
J.K. Park et al.data acquisition and interpretation, or manuscript
preparation.
The corresponding author had full access to all of the
data in the study and had ﬁnal responsibility for the
decision to submit the manuscript for publication.CONFLICT OF INTEREST
E.B. Lee has received consultant's fees from Pﬁzer Inc. The
authors have indicated that they have no other conﬂicts of
interest with regard to the content of this article.SUPPLEMENTARY MATERIAL
Supplementary data associated with this article can be
found in the online version at http://dx.doi.org/
10.1016/j.clinthera.2016.06.016.REFERENCES
1. Haugen IK, Englund M, Aliabadi P, et al. Prevalence,
incidence and progression of hand osteoarthritis in the
general population: the Framingham Osteoarthritis Study.
Ann Rheum Dis. 2011;70:1581–1586.
2. Kalichman L, Hernandez-Molina G. Hand osteoarthritis:
an epidemiological perspective. Semin Arthritis Rheum.
2010;39:465–476.
3. Michon M, Maheu E, Berenbaum F. Assessing health-
related quality of life in hand osteoarthritis: a literature
review. Ann Rheum Dis. 2011;70:921–928.
4. Slatkowsky-Christensen B, Mowinckel P, Loge JH, Kvien
TK. Health-related quality of life in women with sympto-
matic hand osteoarthritis: a comparison with rheumatoid
arthritis patients, healthy controls, and normative data.
Arthritis Rheum. 2007;57:1404–1409.
5. Zhang W, Doherty M, Leeb BF, et al. EULAR evidence
based recommendations for the management of hand
osteoarthritis: report of a Task Force of the EULAR Stand-
ing Committee for International Clinical Studies Including
Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:377–388.
6. Hochberg MC, Altman RD, April KT, et al. American
College of Rheumatology 2012 recommendations for the
use of nonpharmacologic and pharmacologic therapies in
osteoarthritis of the hand, hip, and knee. Arthritis Care Res
(Hoboken). 2012;64:465–474.
7. Kloppenburg M. Hand osteoarthritis-nonpharmacological
and pharmacological treatments. Nat Rev Rheumatol.
2014;10:242–251.
8. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding
peptic ulcer associated with individual non-steroidal anti-
inﬂammatory drugs. Lancet. 1994;343:1075–1078.
9. Grifﬁn MR, Piper JM, Daugherty JR, et al. Nonsteroidal
anti-inﬂammatory drug use and increased risk for pepticAugust 2016ulcer disease in elderly persons. Ann Intern Med. 1991;114:
257–263.
10. Laine L, Curtis SP, Cryer B, et al. Risk factors for NSAID-
associated upper GI clinical events in a long-term pro-
spective study of 34 701 arthritis patients. Aliment
Pharmacol Ther. 2010;32:1240–1248.
11. Kloppenburg M, Stamm T, Watt I, et al. Research in hand
osteoarthritis: time for reappraisal and demand for new
strategies. An opinion paper. Ann Rheum Dis. 2007;66:
1157–1161.
12. Park YG, Ha CW, Han CD, et al. A prospective, random-
ized, double-blind, multicenter comparative study on the
safety and efﬁcacy of Celecoxib and GCSB-5, dried
extracts of six herbs, for the treatment of osteoarthritis
of knee joint. J Ethnopharmacol. 2013;149:816–824.
13. Kim JK, Park SW, Kang JW, et al. Effect of GCSB-5, a
Herbal Formulation, on Monosodium Iodoacetate-
Induced Osteoarthritis in Rats. Evid Based Complement
Alternat Med. 2012;2012:730907.
14. Lee C, Kim S, Lee J, et al. Evaluation of the antinociceptive
properties of GCSB-5, a herbal formulation. Korean J
Pharmacognosy. 2005.
15. Altman R, Alarcon G, Appelrouth D, et al. The American
College of Rheumatology criteria for the classiﬁcation and
reporting of osteoarthritis of the hand. Arthritis Rheum.
1990;33:1601–1610.
16. World Medical Association Declaration of Helsinki: eth-
ical principles for medical research involving human
subjects. JAMA. 2013;310:2191–2194.
17. Moon KW, Lee SS, Kim JH, et al. Cross-cultural adapta-
tion, validation, and responsiveness of the Korean version
of the AUSCAN Osteoarthritis Index. Rheumatol Int.
2012;32:3551–3557.
18. Bellamy N, Campbell J, Haraoui B, et al. Dimensionality
and clinical importance of pain and disability in hand
osteoarthritis: Development of the Australian/Canadian
(AUSCAN) Osteoarthritis Hand Index. Osteoarthritis Carti-
lage. 2002;10:855–862.
19. Pham T, van der Heijde D, Altman RD, et al. OMERACT-
OARSI initiative: Osteoarthritis Research Society Interna-
tional set of responder criteria for osteoarthritis clinical
trials revisited. Osteoarthritis Cartilage. 2004;12:389–399.
20. Shin K, Kim JW, Moon KW, et al. The Efﬁcacy of
Diacerein in Hand Osteoarthritis: A Double-Blind,
Randomized, Placebo-Controlled Study. Clin Ther. 2013.
21. Ehrich EW, Davies GM, Watson DJ, et al. Minimal
perceptible clinical improvement with the Western On-
tario and McMaster Universities osteoarthritis index
questionnaire and global assessments in patients with
osteoarthritis. J Rheumatol. 2000;27:2635–2641.
22. Cooper C, Adachi JD, Bardin T, et al. How to deﬁne
responders in osteoarthritis. Curr Med Res Opin. 2013;29:
719–729.1867
Clinical Therapeutics23. Reginster JY, Reiter-Niesert S,
Bruyere O, et al. Recommenda-
tions for an update of the 2010
European regulatory guideline on
clinical investigation of medicinal
products used in the treatment
of osteoarthritis and reﬂections
about related clinically relevant
outcomes: expert consensus state-
ment. Osteoarthritis Cartilage. 2015.
24. Kvien TK, Fjeld E, Slatkowsky-
Christensen B, et al. Efﬁcacy and
safety of a novel synergistic drug
candidate, CRx-102, in hand os-
teoarthritis. Ann Rheum Dis. 2008;
67:942–948.
25. Brunner E, Puri ML. Nonparamet-
ric methods in design and analysis
of experiments. In: Ghosh S, Rao
CR, eds. Handbook of Statistics
ed 13. New York: Springer-Verlag;
1996.
26. Grifka JK, Zacher J, Brown JP, et al.
Efﬁcacy and tolerability of lumira-
coxib versus placebo in patients
with osteoarthritis of the hand. Clin
Exp Rheumatol. 2004;22:589–596.
27. Dreiser RL, Gersberg M, Thomas
F, Courcier S. [Ibuprofen 800 mg
in the treatment of arthrosis of the
ﬁngers or rhizarthrosis]. Rev Rhum
Ed Fr. 1993;60:836–841.
28. Bhala N, Emberson J, Merhi A,
et al. Vascular and upper gastro-
intestinal effects of non-steroidal
anti-inﬂammatory drugs: meta-
analyses of individual participant
data from randomised trials. Lan-
cet. 2013;382:769–779.
29. Larkai EN, Smith JL, Lidsky MD,
Graham DY. Gastroduodenal mu-
cosa and dyspeptic symptoms in
arthritic patients during chronic
nonsteroidal anti-inﬂammatory
drug use. Am J Gastroenterol.
1987;82:1153–1158.
30. Geusens P, Lems W. Efﬁcacy and
tolerability of lumiracoxib, a highly
selective cyclo-oxygenase-2
(COX2) inhibitor, in the manage-
ment of pain and osteoarthritis.
Ther Clin Risk Manag. 2008;4:337–
344.186831. Silverstein FE, Faich G, Goldstein
JL, et al. Gastrointestinal toxicity
with celecoxib vs nonsteroidal anti-
inﬂammatory drugs for osteoar-
thritis and rheumatoid arthritis:
the CLASS study: A randomized
controlled trial. Celecoxib Long-
term Arthritis Safety Study. JAMA.
2000;284:1247–1255.
32. Keen HI, Wakeﬁeld RJ, Hensor
EM, et al. Response of symptoms
and synovitis to intra-muscular
methylprednisolone in osteoarthritis
of the hand: an ultrasonographic
study. Rheumatology (Oxford). 2010;
49:1093–1100.
33. Wenham CY, Hensor EM, Grainger
AJ, et al. A randomized, double-
blind, placebo-controlled trial of
low-dose oral prednisolone for
treating painful hand osteoarthritis.Rheumatology (Oxford). 2012;51:
2286–2294.
34. Hoes JN, Jacobs JW, Verstappen
SM, et al. Adverse events of low-
to medium-dose oral glucocorti-
coids in inﬂammatory diseases: a
meta-analysis. Ann Rheum Dis.
2009;68:1833–1838.
35. Altman RD, Dreiser RL, Fisher CL,
et al. Diclofenac sodium gel in
patients with primary hand
osteoarthritis: a randomized,
double-blind, placebo-controlled
trial. J Rheumatol. 2009;36:1991–
1999.
36. Bijsterbosch J, Watt I, Meulenbelt
I, et al. Clinical and radiographic
disease course of hand osteoar-
thritis and determinants of out-
come after 6 years. Ann Rheum Dis.
2011;70:68–73.Address correspondence to: Eun Bong Lee, MD, PhD, Division of
Rheumatology, Department of Internal Medicine, Seoul National Uni-
versity College of Medicine, 101 Daehak-ro, Jong no-gu, Seoul 03080,
Republic of Korea. E-mail: leb7616@snu.ac.krVolume 38 Number 8
J.K. Park et al.SUPPLEMENTARY MATERIAL
Supplementry Tables S1–S3.Supplementary Table 1. Summary of the biologic effects of the 6 extracts in GCSB-5.
Extracts Biologic effect
Saposhnikovia divaricata
Schischkin
Anti-inﬂammatory*,†,‡
Achyranthes bidentata Blume Anti-inﬂammatory and reduction of metalloproteinases matrix (MMP)-3 release§
Acanthopanax senticosus Harms Anti-oxidative effect‖
Anti-inﬂammatory: inhibition of AP-1 and/or NF-κB activities¶
Cibotium barometz J. Smith Anti-oxidative effect#
Inhibition of osteoclast formation and activation of osteoblast**
Glycine max Merrill Anti-nocieptive and anti-inﬂammatory effect††
Eucommia ulmoides Oliver Anti-oxidative‡‡
Anti-inﬂammatory: COX-2 suppression§§, Suppression of IL-1, TNF
production‖‖
*Hung JM et al, Evidence-Based Complementary and Alternative Medicine (2016).
†Wang CC et al, Cancer Letters, 145 (1999), pp. 151–157.
‡Ge WH et al, Zhongguo Zhong Yao Za Zhi, 32 (2007), pp. 1777–1779.
§Lee SG et al, Journal of Ethnopharmacology Volume 142, Issue 3, 1 August 2012, pp 634–641.
‖Wang X et al, Journal of Ethnopharmacol. 2010 Feb 3;127(2):424-32.
¶Yamazaki T et al, Toxicology In Vitro. 2007 Dec;21(8):1530-7.
#Luo A et al, International Journal of Biological Macromolecules, 45 (2009), pp. 359–363.
**Cuong NX et al, Journal of Natural Products, 72 (2009), pp. 1673–1677.
††Yim JH et al, International Journal of Molecular Sciences. 2009, 10, pp. 4742-4753.
‡‡IM KR et al, Korean Journal of Biotechnology and Bioengineering, 23 (2008), pp. 329–334.
§§Kim et al Journal of Medicinal Food, 12 (2009), pp. 764–769.
‖‖Zhu et al, 2005, Zhongguo Zhong Yao Za Zhi, 30 (2005), pp. 708–711.Supplementary Table 2. Association between
leukopenia and URI
in GCSB-5 group.
Leukopenia (þ) Leukopenia (-) Total
URI (þ) 0 16 16
URI (-) 9 84 93
Total 9 100 109
P¼0.3512 by Fisher’s exact test.
URI, upper respiratory infection.
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Supplementary Table 3. Mean change from baseline in efficacy outcomes in the two study groups
Outcomes GCSB-5 (n ¼109) Placebo (n ¼ 106)
AUSCAN pain change from baseline, mean (SD)
Week 4 -10.2 (17.1) -5.7(19.3)
Week 8 -12.4 (19.2) -6.7 (21.9)
Week 12 -14.6 (21.5) -8.8 (23.5)
Week 16 -14.4 (19.5) -6.5(25.7)
AUSCAN stiffness, change from baseline, mean (SD)
Week 4 -10.2 (24.4) -9.3 (23.5)
Week 8 -13.6 (25.0) -10.1 (28.0)
Week 12 -17.0 (27.4) -12.8 (28.1)
Week 16 -12.4 (26.6) -9.7 (29.6)
AUSCAN function, change from baseline, mean (SD)
Week 4 -8.3 (21.3) -4.4 (18.1)
Week 8 -9.6 (22.9) -6.0 (21.8)
Week 12 -12.0 (25.5) -7.3 (24.1)
Week 16 -11.0 (23.6) -5.4 (26.4)
Patient global assessment, change from baseline, mean (SD)
Week 4 -9.7 (21.6) -4.7 (19.3)
Week 8 -11.8 (23.1) -4.1 (22.9)
Week 12 -13.8 (23.9) -7.5 (25.8)
Week 16 -10.4 (24.2) -6.0 (25.4)
Physician global assessment, change from baseline, mean (SD)
Week 4 -12.5 (16.1) -9.7 (15.4)
Week 8 -17.3 (17.8) 13.0 (17.8)
Week 12 -18.5 (17.8) -14.3 (18.2)
Week 16 -13.4 (17.5) -9.6 (17.7)
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